Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04145440 · ClinicalTrials.gov registry record · Phase 1
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
A Phase 1 study, sponsored by HI-Bio, A Biogen Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04145440 is a Phase 1 study that has completed, run by HI-Bio, A Biogen Company. The registered enrollment target is 31 participants.
The verdict
NCT04145440, a Phase 1 study, has completed, sponsored by HI-Bio, A Biogen Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)
Interventions
- DRUG MOR202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2022-08-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04145440
The ClinicalTrials.gov registry entry for NCT04145440 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HI-Bio, A Biogen Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MOR202 is the first listed.
NCT04145440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04145440 about?
NCT04145440 is a clinical study titled "Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)". This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)
What is the current status of trial NCT04145440?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2019-10-15. Estimated completion is 2022-08-02.
What interventions are being tested in trial NCT04145440?
The interventions under investigation include: MOR202 (DRUG).
Who is sponsoring clinical trial NCT04145440?
This trial is sponsored by HI-Bio, A Biogen Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.